TSHZ2

Summary

TSHZ2 (teashirt zinc finger homeobox 2, HGNC:13010) is a protein-coding gene on chromosome 20q13.2, encoding Teashirt homolog 2 (Q9NRE2). Probable transcriptional regulator involved in developmental processes.

This gene is a member of the teashirt C2H2-type zinc-finger protein family of transcription factors. This gene encodes a protein with five C2H2-type zinc fingers, a homeobox DNA-binding domain and a coiled-coil domain. This nuclear protein is predicted to act as a transcriptional repressor. This gene is thought to play a role in the development and progression of breast and other types of cancer. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 128553 — RefSeq curated summary.

At a glance

• GWAS associations: 39
• Clinical variants (ClinVar): 177 total
• MANE Select transcript: NM_173485

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13010
Approved symbol	TSHZ2
Name	teashirt zinc finger homeobox 2
Location	20q13.2
Locus type	gene with protein product
Status	Approved
Aliases	ZABC2, OVC10-2, TSH2
Ensembl gene	ENSG00000182463
Ensembl biotype	protein_coding
OMIM	614118
Entrez	128553

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 nonsense_mediated_decay

ENST00000371497, ENST00000603338, ENST00000605656, ENST00000626626

RefSeq mRNA: 2 — MANE Select: NM_173485 NM_001193421, NM_173485

CCDS: CCDS33490, CCDS54474

Canonical transcript exons

ENST00000371497 — 3 exons

Exon	Start	End
ENSE00001455378	53487144	53495330
ENSE00001455380	53253499	53256571
ENSE00001455381	52972358	52973333

Expression profiles

Bgee: expression breadth ubiquitous, 230 present calls, max score 94.74.

FANTOM5 (CAGE): breadth broad, TPM avg 5.3915 / max 301.4259, expressed in 729 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185328	3.0106	615
185330	0.8350	309
185335	0.4477	229
185334	0.3181	163
185337	0.2645	96
185336	0.1699	81
185329	0.1187	44
185333	0.1136	54
185331	0.0919	31
185332	0.0215	6

Top tissues by expression

274 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	94.74	gold quality
corpus epididymis	UBERON:0004359	90.38	gold quality
caput epididymis	UBERON:0004358	90.17	gold quality
parietal pleura	UBERON:0002400	89.38	gold quality
mammary duct	UBERON:0001765	88.96	gold quality
epithelium of mammary gland	UBERON:0003244	88.13	gold quality
omental fat pad	UBERON:0010414	87.88	gold quality
peritoneum	UBERON:0002358	87.85	gold quality
adipose tissue of abdominal region	UBERON:0007808	87.67	gold quality
tendon of biceps brachii	UBERON:0008188	87.26	gold quality
cauda epididymis	UBERON:0004360	86.99	gold quality
right ovary	UBERON:0002118	86.40	gold quality
mammary gland	UBERON:0001911	86.23	gold quality
thoracic mammary gland	UBERON:0005200	86.15	gold quality
adrenal tissue	UBERON:0018303	85.96	gold quality
pleura	UBERON:0000977	85.57	gold quality
left ovary	UBERON:0002119	85.29	gold quality
colonic epithelium	UBERON:0000397	85.24	gold quality
right adrenal gland	UBERON:0001233	85.16	gold quality
left adrenal gland	UBERON:0001234	85.16	gold quality
left adrenal gland cortex	UBERON:0035825	85.09	gold quality
adrenal gland	UBERON:0002369	84.95	gold quality
ovary	UBERON:0000992	84.38	gold quality
adrenal cortex	UBERON:0001235	84.29	gold quality
adipose tissue	UBERON:0001013	84.07	gold quality
gall bladder	UBERON:0002110	83.91	gold quality
right adrenal gland cortex	UBERON:0035827	83.82	gold quality
connective tissue	UBERON:0002384	83.55	gold quality
olfactory bulb	UBERON:0002264	83.35	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	83.25	gold quality

Single-cell (SCXA)

Detected in 18 experiment(s), a significant marker in 18.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	6075.89
E-HCAD-35	yes	2472.77
E-MTAB-11268	yes	2147.43
E-HCAD-30	yes	1810.68
E-HCAD-25	yes	1694.96
E-MTAB-9906	yes	836.11
E-MTAB-9841	yes	661.97
E-CURD-95	yes	271.40
E-GEOD-135922	yes	163.98
E-MTAB-8142	yes	46.74
E-GEOD-134144	yes	45.63
E-HCAD-10	yes	33.88
E-MTAB-6701	yes	29.72
E-CURD-119	yes	25.38
E-ANND-3	yes	16.02

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

269 targeting TSHZ2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-520D-5P	99.98	73.34	4883

Literature-anchored findings (GeneRIF, showing 5)

• Mutations in TSHZ2 and TSHZ3 are not a major cause of pelvi-ureteric junction obstruction, at least in Albanian and Macedonian populations. (PMID:19745106)
• TSHZ3 gene promoter was found to be methylated in all the breast/prostate cancer cell lines and some of the breast cancer clinical specimens while the TSHZ2 gene promoter was unmethylated except for the MDA-MB-231 breast cancer cell line. (PMID:21423795)
• Down-regulation of TSHZ2 is crucial for mammary tumorigenesis via the activation of GLI1. (PMID:26744317)
• Overexpression of Teashirt Homolog 2 suppresses cell proliferation and predicts the favorable survival of Lung Adenocarcinoma. (PMID:33850468)
• TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. (PMID:34158398)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tshz2	ENSDARG00000079201
mus_musculus	Tshz2	ENSMUSG00000047907
rattus_norvegicus	Tshz2	ENSRNOG00000048433
drosophila_melanogaster	tsh	FBGN0003866
drosophila_melanogaster	tio	FBGN0028979

Paralogs (2): TSHZ3 (ENSG00000121297), TSHZ1 (ENSG00000179981)

Protein

Protein identifiers

Teashirt homolog 2 — Q9NRE2 (reviewed: Q9NRE2)

Alternative names: Ovarian cancer-related protein 10-2, Zinc finger protein 218

All UniProt accessions (3): Q9NRE2, B1H0U8, S4R3C8

UniProt curated annotations — full annotation on UniProt →

Function. Probable transcriptional regulator involved in developmental processes. May act as a transcriptional repressor (Potential).

Subunit / interactions. Interacts (via homeobox domain) with APBB1 (via PID domain 1).

Subcellular location. Nucleus.

Tissue specificity. Expressed in brain; strongly reduced in post-mortem elderly subjects with Alzheimer disease.

Post-translational modifications. Sumoylated.

Similarity. Belongs to the teashirt C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NRE2-1	1	yes
Q9NRE2-2	2

RefSeq proteins (2): NP_001180350, NP_775756* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001356	HD	Domain
IPR013087	Znf_C2H2_type	Domain
IPR027008	Teashirt_fam	Family
IPR058631	TSHZ1-3_homeodomain	Domain

Pfam: PF26094

UniProt features (40 total): cross-link 12, region of interest 6, zinc finger region 5, compositionally biased region 5, sequence conflict 5, sequence variant 2, chain 1, coiled-coil region 1, modified residue 1, splice variant 1, DNA-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NRE2-F1	54.88	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (13): 980, 188, 306, 315, 417, 461, 480, 497, 601, 652, 800, 820, 966

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 245 (showing top): WANG_CLIM2_TARGETS_UP, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, CREBP1_Q2, FOXD3_01, NKX61_01, PAX8_B, TCF4_Q5, HFH8_01, TGIF_01, HFH4_01, HFH3_01, LIAO_METASTASIS, TGACATY_UNKNOWN, TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN, HFH1_01

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of gene expression (GO:0010468)

GO Molecular Function (5): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
gene expression	1
regulation of macromolecule biosynthetic process	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

874 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TSHZ2	GLI1	P08151	492
TSHZ2	LGALS4	P56470	488
TSHZ2	CBY1	Q9Y3M2	452
TSHZ2	SMARCE1	Q969G3	442
TSHZ2	EXD1	Q8NHP7	438
TSHZ2	HOXA7	P31268	423
TSHZ2	ZFHX2	Q9C0A1	423
TSHZ2	ZFP64	Q9NTW7	400
TSHZ2	ZSCAN2	Q7Z7L9	378
TSHZ2	D6RC18	D6RC18	372
TSHZ2	KIF26A	Q9ULI4	355
TSHZ2	ZNF503	Q96F45	340
TSHZ2	HMX1	Q9NP08	336
TSHZ2	CFAP20DC	Q6ZVT6	321
TSHZ2	PKNOX2	Q96KN3	321
TSHZ2	TSKU	Q8WUA8	321

IntAct

62 interactions, top by confidence:

A	B	Type	Score
TSHZ2	COG3	psi-mi:“MI:0915”(physical association)	0.560
TSHZ2	PHAF1	psi-mi:“MI:0915”(physical association)	0.560
RINT1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
MCC	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
TRAF1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
CCDC88B	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
TSHZ2	TFIP11	psi-mi:“MI:0915”(physical association)	0.560
BACH2	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
SPTA1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
GRIPAP1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
RABEP1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
CRACR2B	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
CCDC57	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
TRAF2	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
GIGYF1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
CNTROB	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
PIBF1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
COG3	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
PHAF1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
PNMA1	TSHZ2	psi-mi:“MI:0915”(physical association)	0.560
PYCARD	MYO1C	psi-mi:“MI:0914”(association)	0.350
TSHZ1	MEIS2	psi-mi:“MI:0914”(association)	0.350
TSHZ2	NDUFS4	psi-mi:“MI:0914”(association)	0.350
RBBP4	PHF20L1	psi-mi:“MI:0914”(association)	0.350
TSHZ2	RINT1	psi-mi:“MI:0915”(physical association)	0.000
TSHZ2	MCC	psi-mi:“MI:0915”(physical association)	0.000
TSHZ2	TRAF1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (36): TSHZ2 (Affinity Capture-MS), TSHZ2 (Biochemical Activity), TSHZ2 (Affinity Capture-RNA), TSHZ2 (Affinity Capture-RNA), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid), TSHZ2 (Two-hybrid)

ESM2 similar proteins: A0A0R4IYX6, A0A1D5NVS8, A0A1L8H0H2, A0AVK6, A5GFT6, A7XYH5, A7XYJ6, B7ZS37, B8A5Y1, D4A666, E1B7L7, E1BKK0, E1BLP6, F1LMN3, F6YVB9, F8VPJ6, Q12766, Q13029, Q14B70, Q2HNT1, Q2HNT2, Q2KHR2, Q4V9H5, Q58FA4, Q5DTH5, Q5ZIE8, Q5ZIX8, Q5ZJ69, Q5ZM88, Q63679, Q63755, Q68FE9, Q69ZF8, Q6DRC5, Q6P4F7, Q6PCM1, Q6ZSZ6, Q76L83, Q80Y19, Q8BHZ4

Diamond homologs: A5GFT6, B3DJM5, D3ZKB9, P22265, Q2HNT1, Q2HNT2, Q5DTH5, Q63HK5, Q68FE9, Q6ZSZ6, Q8CGV9, Q9NRE2, Q9U3V5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

177 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	161
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3333 predictions. Top by Δscore:

Variant	Effect	Δscore
20:53253494:TGCA:T	acceptor_loss	1.0000
20:53253497:A:AG	acceptor_gain	1.0000
20:53253497:AGG:A	acceptor_loss	1.0000
20:53253498:G:GG	acceptor_gain	1.0000
20:53253498:GGC:G	acceptor_gain	1.0000
20:53253497:AG:A	acceptor_gain	0.9900
20:53253498:GG:G	acceptor_gain	0.9900
20:53253498:GGCT:G	acceptor_gain	0.9900
20:53253498:GGCTA:G	acceptor_gain	0.9900
20:53256443:GT:G	donor_gain	0.9900
20:53257773:T:G	donor_gain	0.9900
20:53021933:T:TG	donor_gain	0.9800
20:53142384:G:GT	donor_gain	0.9800
20:53142394:GC:G	donor_gain	0.9800
20:53178148:T:A	acceptor_gain	0.9800
20:53494870:GCA:G	acceptor_gain	0.9800
20:52973331:CAGG:C	donor_loss	0.9700
20:52973332:AGGT:A	donor_loss	0.9700
20:52973333:GGT:G	donor_loss	0.9700
20:52973334:G:T	donor_loss	0.9700
20:52973335:T:G	donor_loss	0.9700
20:52996488:T:TA	donor_gain	0.9700
20:52996489:A:AA	donor_gain	0.9700
20:53037559:T:G	acceptor_gain	0.9700
20:53142423:TCAC:T	donor_gain	0.9700
20:53256445:G:GG	donor_gain	0.9700
20:53270359:GCCT:G	donor_gain	0.9700
20:53021924:G:GG	donor_gain	0.9600
20:53142399:T:G	donor_gain	0.9600
20:53178150:C:CA	acceptor_gain	0.9600

AlphaMissense

6877 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:52973301:G:T	R3M	1.000
20:53254102:T:C	F215S	1.000
20:53254107:T:C	C217R	1.000
20:53254109:C:G	C217W	1.000
20:53254147:T:C	L230P	1.000
20:53254282:T:A	L275Q	1.000
20:53254282:T:C	L275P	1.000
20:53254287:T:A	C277S	1.000
20:53254287:T:C	C277R	1.000
20:53254288:G:A	C277Y	1.000
20:53254288:G:C	C277S	1.000
20:53254288:G:T	C277F	1.000
20:53254289:T:G	C277W	1.000
20:53254296:T:C	C280R	1.000
20:53254297:G:A	C280Y	1.000
20:53254297:G:T	C280F	1.000
20:53254298:T:G	C280W	1.000
20:53254308:T:C	F284L	1.000
20:53254309:T:C	F284S	1.000
20:53254310:T:A	F284L	1.000
20:53254310:T:G	F284L	1.000
20:53254318:T:A	L287H	1.000
20:53254327:T:C	L290S	1.000
20:53254327:T:G	L290W	1.000
20:53254329:A:C	S291R	1.000
20:53254331:C:A	S291R	1.000
20:53254331:C:G	S291R	1.000
20:53254335:C:G	H293D	1.000
20:53254339:T:A	M294K	1.000
20:53254339:T:C	M294T	1.000

dbSNP variants (sampled 300 via entrez): RS1000002403 (20:53361489 C>CT), RS1000004407 (20:53390838 C>T), RS1000013651 (20:53304085 A>G), RS1000016957 (20:53311536 C>T), RS1000021059 (20:53072401 G>A), RS1000022510 (20:53462037 G>A), RS1000023505 (20:53492442 A>G), RS1000024801 (20:53228908 G>T), RS1000028262 (20:53110705 G>A), RS1000031476 (20:53207852 G>T), RS1000034347 (20:53027142 A>G), RS1000036726 (20:53105658 A>AT), RS1000049841 (20:52990797 G>A), RS1000060834 (20:53368062 C>T), RS1000062685 (20:53304348 T>C)

Disease associations

OMIM: gene MIM:614118 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary amenorrhea (MONDO:1060208)

Orphanet (1): Microphthalmia-anophthalmia-coloboma (Orphanet:98555)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

39 associations (top):

Study	Trait	p-value
GCST000499_6	Hemoglobin	1.000000e-10
GCST003059_22	Parkinson’s disease	1.000000e-06
GCST003560_18	Coronary artery aneurysm in Kawasaki disease	7.000000e-06
GCST004125_21	Type 2 diabetes (age of onset)	5.000000e-06
GCST005441_11	Alcohol consumption (max-drinks)	9.000000e-06
GCST005651_9	Urinary metabolite levels in chronic kidney disease	3.000000e-08
GCST007324_103	Adventurousness	1.000000e-08
GCST007325_1	General risk tolerance (MTAG)	5.000000e-09
GCST007325_115	General risk tolerance (MTAG)	4.000000e-10
GCST007798_111	Asthma	5.000000e-10
GCST007800_84	Asthma (childhood onset)	1.000000e-07
GCST008477_34	Emphysema annual change measurement in smokers (adjusted lung density)	4.000000e-06
GCST008477_9	Emphysema annual change measurement in smokers (adjusted lung density)	3.000000e-06
GCST009307_9	Spatial memory	3.000000e-06
GCST009379_300	Type 2 diabetes	7.000000e-09
GCST009615_21	Triglyceride levels x loop diuretics use interaction	9.000000e-06
GCST010241_316	Apolipoprotein A1 levels	2.000000e-08
GCST010244_371	Triglyceride levels	6.000000e-11
GCST010577_8	Crohn’s disease	8.000000e-06
GCST012490_39	Femur bone mineral density x serum urate levels interaction	8.000000e-12
GCST012490_602	Femur bone mineral density x serum urate levels interaction	2.000000e-10
GCST90000047_266	Age at first sexual intercourse	3.000000e-08
GCST90020024_807	A body shape index	3.000000e-14
GCST90020024_808	A body shape index	2.000000e-17
GCST90020025_1682	Waist-to-hip ratio adjusted for BMI	5.000000e-10
GCST90020025_1683	Waist-to-hip ratio adjusted for BMI	2.000000e-09
GCST90020025_1684	Waist-to-hip ratio adjusted for BMI	3.000000e-16
GCST90020025_1760	Waist-to-hip ratio adjusted for BMI	1.000000e-26
GCST90020025_1761	Waist-to-hip ratio adjusted for BMI	3.000000e-10
GCST90020025_1762	Waist-to-hip ratio adjusted for BMI	2.000000e-08

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004509	hemoglobin measurement
EFO:0005116	urinary metabolite measurement
EFO:0008579	risk-taking behaviour
EFO:0007626	emphysema imaging measurement
EFO:0004874	memory performance
EFO:0004530	triglyceride measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004531	urate measurement
EFO:0009749	age at first sexual intercourse measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2010156	TSHZ2		0.00	0

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation, increases expression	7
Benzo(a)pyrene	decreases expression, affects methylation	3
Aflatoxin B1	decreases expression, increases methylation	3
entinostat	decreases expression, increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
TAK-243	increases sumoylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
trichostatin A	decreases expression	1
sulforaphane	decreases expression	1
manganese chloride	increases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	affects methylation	1
coumarin	decreases phosphorylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Panobinostat	affects cotreatment, decreases expression	1
Arbutin	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Lead	increases expression	1
Manganese	increases expression	1

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT07164248	Not specified	COMPLETED	Evaluation of Bone Mineral Density Indications and Outcomes in Female Adolescents: Implications for Early Detection of Osteopenia/Osteoporosis and Gynecologic Practice